secwatch.observer — SEC 8-K summary
======================================

Issuer:     BNB PLUS CORP. (BNBX)
CIK:        0000744452
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001104659-25-064106
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Applied DNA restructures to focus on LineaRx; cuts 27% of staff, shuts clinical lab
--------------------------------------------------------------------------------

- Workforce reduction of 27% (projected 23% payroll cut); ceases operations at Applied DNA Clinical Labs.
- One-time charges of ~$300k; majority of costs expected by Sept 30, 2025.
- CEO Judy Murrah takes 15% salary reduction to $340k/year.
- Company ends May 2025 with ~$4.8M cash; cumulative headcount reduction of 39% since Dec 2024.
- Restructuring positions LineaRx synthetic DNA manufacturing as sole focus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/0001104659-25-064106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/tm2519488d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-064106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer